Last reviewed · How we verify

NCT06340204

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Recruiting now Phase 1 Last updated 3 April 2024
What this trial tests

Phase 1 trial testing Irinotecan Hydrochloride Liposome Injection in Ewing Sarcoma in 44 participants. Currently enrolling.

Timeline
25 March 2024
Primary endpoint
25 March 2026
25 December 2026

Quick facts

Lead sponsorPeking University People's Hospital
PhasePhase 1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment44
Start date25 March 2024
Primary completion25 March 2026
Estimated completion25 December 2026
Sites3 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Peking University People's Hospital

Who can join

Adults 8 to 40, any sex, with Ewing Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators explored the safety and activity of weekly irinotecan liposomes in patients with relapsed and metastatic Ewing Sarcoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Irinotecan Hydrochloride Liposome Injection

Trials testing the same drug.

Other recruiting trials for Ewing Sarcoma

Currently open trials in the same condition.

Other Peking University People's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06340204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing